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Gene therapy by expression constructs or down-regulation of certain genes has shown great 











materials dependents on the development of biocompatible gene carriers. There are enormous 
various compounds widely investigated to be used as non-viral gene carriers including lipids, 
polymers, carbon materials, and inorganic structures. In this review, we will discuss the recent 
discoveries on non-viral gene delivery systems. We will also highlight the in vivo gene delivery 
mediated by non-viral vectors to treat cancer in different tissue and organs including brain, 
breast, lung, liver, stomach, and prostate. Finally, we will delineate the state-of-the-art and 
promising perspective of in vivo gene editing using non-viral nano-vectors. 
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1. Introduction  
Since the elucidation of the molecular mechanisms of several diseases along with the discovery 
of nucleic acid structure, the replacement of defective genes with functional versions has been 
considered as a new therapeutic paradigm called “gene therapy” (1, 2). Gene therapy is carried 
out by expression constructs in order to increase the production of specific proteins inside the 
cells. On the other hand, down-regulation of specific genes has shown great potential for the 
treatment of various diseases (3). Therefore, the modulation or silencing of such genes using 
antisense or siRNA has opened up new horizons for the introduction of a novel therapeutic 
strategy for incurable diseases (4). Recently, the breakthrough of chimeric antigen receptor T cell 
immunotherapy and gene editing platforms have revolutionized the classic gene therapy 
approaches.  
The broad clinical application of nucleic acid materials as a drug is significantly dependent on 











low toxicity (5). The evolution pathway of viruses enabled them to pack the genetic materials, 
protect them against degrading enzymes (e.g., nucleases) and transfer them into the target cells 
with high specificity. As of 2017, around 67% of all gene therapy clinical trials were carried out 
by viral vectors (6). However, there are several significant concerns regarding the application of 
viruses as a cargo, including immunogenicity, insertional mutagenesis, as well as reports of 
deaths following the administration of viral vectors for gene delivery. Also, the limited capacity 
of viruses for gene delivery and expensive production methods of engineered viruses for large-
scale production has hampered their application as a promising vector (7, 8). For example, 
Glybera (alipogene tiparvovec) which was approved in 2012 for the treatment of familial 
lipoprotein lipase deficiency (LPLD) withdrawn from the market due to the high price of 1 
million US dollar per single injection which made it as the most expensive medicine in the world 
at that time (9). Therefore, considerable attention has been directed to the application of a new 
class of carriers with the ability to mimic the virus properties for infection, promote the cellular 
entry of nucleic acids and their release inside the cells (e.g., cytosol or nucleus) (10, 11). These 
carriers are called as non-viral vectors and must be able to interact with nucleic acids to condense 
them outside the cells and protect the genetic materials from various degrading factors (12, 13).  
There are various enormous compounds widely investigated to be used as non-viral gene 
carriers, including peptides, lipids, and polymers. Among these different materials, polycationic 
polymers have been widely used due to their specific characteristics (14). The molecular 
structure of these compounds is stable and enables them to act as a scaffold for further 
modifications in order to improve their properties for in vivo applications. For instance, cationic 
polymers contain several amine groups in their structure, making them as positively charged 











charged nucleic acid materials and forming polyelectrolyte complexes (i.e., polyplex). These 
unique supramolecular assemblies could interact with the negatively-charged components on the 
plasma membrane and facilitate the cell entry via adsorptive endocytosis (15). The translation of 
polyplexes from bench to bed is still in the beginning. However, there are some polycationic 
compounds in different phases of a clinical trial for the treatment of various diseases, including 
cystic fibrosis, AIDS, bladder and ovarian cancers, as well as melanoma and inherited TTR 
amyloidosis (Tables 1 and 2) (16-19). Various polycations have been used in these clinical trials, 
such as unmodified polyethylenimine (PEI), which is the most extensively investigated 
polycation for gene delivery. Also, the conjugated forms of PEI with cholesterol and mannose 
have been used for some clinical applications (20, 21). On the other hand, PEG conjugated, and 
transferrin-conjugated polylysine have been applied in human clinical trials (22). The 
polycations used for human gene delivery showed that the application of such materials in 
human is highly dependent on the optimization of their intrinsic properties including cytotoxicity 
(23). In other words, their clinical application might be hampered by the significant toxic effects 
result from their cationic nature, which is a prerequisite for the formation of nano-sized particles 
(24). The dilemma between higher efficiency of gene transfer and cytotoxic effects of 
polycations has led researchers to seek for different conjugation strategies for improving the 
properties of these materials for human application (25). In addition, learning from nature directs 
investigators to design precise and sequence-defined polymers. This novel class of polycationic 
compounds could be called artificial viruses since they are not a real virus particle. However, 
they contain the essential parts of a virus, which have shown crucial role in gene delivery. These 
particles must be able to pack nucleic acid materials and protect them in the extracellular 











targeting ligands in order to direct them into the specific cells or subcellular organelles (4, 26, 
27). On the other hand, the dissociation of nucleic acid from its cargo could be considered as the 
rate-limiting step in successful gene delivery. Although the association of nucleic acid and 
vehicle is essential for complex formation outside the cells, the release of nucleic acids in cytosol 
or nucleus is a determining factor for the biological effects of nucleic acid therapeutics. It seems 
that the bio-inspired polycationic carriers may open up new avenues for the clinical translation of 
non-viral gene delivery systems.   
 
2. From bench to bedside: an overview 
There are several intra- and extra-cellular barriers determining the pharmacokinetics and 
biodistribution of the non-viral gene carrier in the human body. These factors, along with the 
intrinsic characteristics of the carrier and nucleic acid material, play a crucial role in choosing the 
best and more efficient route for administration (4). Various types of nucleic acids could be 
applied as therapeutic agents in gene therapy. The determining factor to choose the best nucleic 
acid material is the purpose of the treatment. In some diseases or pathologic conditions, the 
expression of specific genes may be reduced. Therefore, the essential need is to compensate the 
lower levels of gene expression by transferring a construct enabling the cells to up-regulate the 
specific gene. In these cases, a plasmid DNA (pDNA) could be considered as a tool to enhance 
gene expression. Plasmid DNA-based gene therapies could be categorized as the classic gene 
therapy in which the lack or loss of function in a cell is attributed to the low expression of a 
specific gene. The concept of using the pDNA as a therapeutic agent comes from the fact that 
this loss of function could be compensated by transferring the corrected or enhanced sequences 











application for gene therapy seems to be simple, there are several problems hampering its 
clinical application. Naked pDNA delivery is not generally satisfactory due to the low uptake, 
degradation in the bloodstream, and poor pharmacokinetic properties. In addition, pDNA must 
be able to cross the nuclear membrane to access the transcriptional machinery of the cells (32). A 
successful gene carrier must be able to pack the plasmid DNA outside the cells and protect it 
against degrading agents. On the other hand, the carrier system must allow the pDNA to be 
accessed by the transcriptional machinery of the cells for the production of mRNA. Therefore, an 
efficient plasmid DNA delivery system is needed to protect the plasmid outside the cells, 
particularly against degrading enzymes, enhance their cellular uptake, preferably to the target 
cells and improve their pharmacokinetic properties for in-vivo applications. Since pDNA 
delivery has shown some difficulties particularly in terms of in-vivo applications, an alternative 
strategy to improve the gene expression level is mRNA therapy (33). mRNA therapy has shown 
great advantages compared with pDNA in recent years (34).The site of action for mRNA is 
cytoplasm, whereas the pDNA must be entered to cell nucleus for efficient gene expression (35). 
Using mRNA does not need to overcome the nuclear envelope as one of the toughest barriers 
limiting gene delivery. Since the site of action for mRNA is the cytoplasm, the risk of insertional 
mutagenesis could be ignored. Although the immunogenic response against pDNA is limited to 
the CpG motif of plasmids by tool like receptors, the same responses against RNA sequences are 
remarkably lower. One more advantage of mRNA versus pDNA therapy is that the size of 
mRNA is smaller than pDNA. Therefore, it could be transferred to the host cells more easily.  
The last but not least advantage of mRNA application for gene therapy is the rapid responses 
following transfection. The transfection of pDNA takes several hours or days since the pDNA 











accessed by the ribosome for the production of proteins. On the other hand, mRNA directly 
enters the cytoplasm and interacts with ribosome for protein production. These unique properties 
have made mRNA as a potential candidate not only for gene therapy but also for vaccine 
development particularly for the immunization against widespread viruses including SARS-
CoV-2 (36).  However, the major concerns regarding the application of mRNA for gene therapy 
are its unstable nature and the existence of degrading enzymes such as RNases in the extra- and 
intra-cellular environments (37, 38). To overcome these problems, new developments, including 
SNIM (stabilized non-immunogenic mRNA), have been introduced in which the modified 
nucleotides could be incorporated into the mRNA structure to increase its stability and reduce its 
immunogenicity (4, 39-41).  
The aim of gene therapy is not just increasing the expression of certain gene as it was expected in 
previous decades. There are several pathological conditions related to the genes over-expression. 
In such conditions, the gene therapy goal would be silencing the target genes. The knock-down 
of such genes could be achieved by different nucleic acid materials, including antisense and 
siRNA. It must be considered that there are some differences between gene therapy and 
oligonucleotide therapy (42). Oligonucleotide-based medications such as antisense do not need 
the transcriptional and translational machinery of the cells while the conventional gene therapy is 
based on the replacement of defected genes by the functional ones as well as the introduction of 
new gene into the cells including germlines or somatic cells (43). Antisense technology is 
defined as a powerful tool to down-regulate a specific gene by transferring the antisense strand to 
the cells with the ability to interact with the sense strand. The base pairing between the sense and 
antisense strands results in the translational block (44, 45). On the other hand, RNAi technology 











protein production. Antisense, miRNA, and siRNA are ribonucleic acid-based materials (46). 
Therefore, the major concerns for RNA-based therapeutics do already exist for them. The 
successful delivery of such materials to the cells or tissues and organs need a delivery vehicle 
designed to circumvent the barriers for their efficient delivery (47-49).  
 A successful non-viral delivery system must have a favorable circulation time allowing the 
carrier to penetrate the target tissue with low toxic effects as well as biocompatibility and 
biodegradability of the carrier system (34, 50). Once taken up by the target cells, the delivery 
system must be able to be unpacked and release the therapeutic nucleic acid inside the cell. In 
other words, vector unpackaging inside the cells could be considered as an important factor for 
high transfection efficacy while the formation of stable complexes (i.e., packaging) outside the 
cells is a key factor for achieving successful gene delivery (5, 30, 51).  
Another factor affecting the transfection efficiency is the size and zeta potential of the 
complexes. It seems that the particles with the size range of 50-100 nm and zeta potential of 
around ±10 mV have shown the best results to access the tumor microenvironment with the 
lowest uptake by the reticuloendothelial system (RES) (25, 50, 52, 53). The nucleic acid 
containing particles have shown short circulation half-life limiting their access to the target site 
while the larger complexes are not able to cross through the capillary fenestra to reach the tumor 
site. Prolonged blood circulation time is a prerequisite for gene delivery using non-viral gene 
carriers (54). There are several various molecules conjugated on the surface of polymeric 
vehicles to make them as stealth carriers, including polyvinyl alcohol (PVA), poly (glycerol), 
poly-N-vinylpyrrolidone and poly (ethylene glycol) (PEG) (32, 55-58). All these materials create 
a steric stabilization effect leading to the prolonged circulation half-life by prevention of 











layer on the surface of the carriers reduces the risk of aggregation and increases colloidal 
stability. The reduction of the interaction between the stealth gene carriers and serum 
components reduces the recognition of the vehicles by mononuclear phagocyte system (MPS), 
including macrophages, which in turn leads to enhanced circulation time (58). In order to direct 
the carriers into the precise site of action, smart gene carriers have been designed. These carriers 
could be targeted to the specific receptors by the conjugation of small molecules as well as 
macromolecules including monoclonal antibodies or aptamers (59-61). Once the nano-carriers 
reach the cells, they may enter endosomal compartment, which degrades the nucleic acid 
therapeutics and leads to failed transfection. Hence, the promotion of proton sponge effect or the 
conjugation of membrane fusogenic compounds could be considered as brilliant strategies to 
overcome the endo/lysosomal barrier (62, 63). While the siRNA site of action is the cytosolic 
environment, plasmids must be able to cross the nuclear barrier. It has been shown that the 
molecules with the molecular mass of 40-70 kDa (10-25 nm) are able to passively diffuse via 
nuclear pores. However, the exact mechanism of nuclear entry is not completely understood (4, 
64). It is not clear whether the polyplexes goes under vector unpackaging outside the nucleus or 
the transcriptional machinery of the cell dissociate the nucleic acids from the carrier inside the 
nucleus. Regardless of the mechanism, it has been demonstrated that cell cycle may have a 
crucial impact on the cell entry. The cells at the phases of S/G2 have shown the highest 
transfection efficiency. However, most cells are not in the dividing phase in vivo; therefore the 
alternative approaches, including the conjugation of nuclear localization signals (NLS), must be 
employed to increase nucleus entry (65, 66). The real value of these important findings is 
dependent on their translation to clinical application. The approval of patisiran (Onpattro
®
) as the 











amyloidosis opened up new horizons for the scientists to seek for the efficient delivery systems 
enabling the nucleic acids to be used as therapeutic agents. Patisiran has been formulated as lipid 
nanoparticles (NPs) and is used by intravenous infusions while the second approval for siRNA-
based therapeutics belongs to givosiran (Givlaari
®
) (67-69). Givosiran has been prepared as N-
acetylgalactosamine (GalNAc) conjugated siRNA and is administrated subcutaneously. The first 
polymer-based gene therapy investigation in human was carried by Transferrin-polylysine 
(adenovirus-enhanced transferrinfection; AVET) carrier in order to transfer the plasmid encoding 
IL-2 gene for the treatment of melanoma (70). In the first-ever human study of polyplexes, the 
ex-vivo gene transfer was performed to deliver the plasmid DNA into the patient cells. PEG 
conjugated polylysine was used to transfer the pDNA to treat cystic fibrosis as a nasal drug 
delivery system (16). In another study to design a vaccine for HIV, mannose conjugated PEI was 
prepared as the carrier for the plasmid encoding various HIV antigens and used as a dermal 
formulation in a human clinical trials (71). The intraperitoneal injection of PEG-PEI-Cholesterol 
to transfer IL-12 plasmid was also used for ovarian cancer treatment (72). The intravenous 
injection of transferrin-cyclodextrin oligocation complexed with siRNA to silence ribonucleotide 
reductase M2(RRM2) was applied in various solid tumors (22). Since various routes of 
administration have been used to transfer non-viral delivery systems for gene therapy, it seems 
that the route is highly dependent on the characteristics of the carrier and nucleic acids as well 
the prepared complex and the final formulation. It seems that there is no restrict limitation for a 
specific route of administration for non-viral gene delivery carriers at least in the theoretical 
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* Patient-derived xenograft model is a tumor model in which the tumor cells from patients are 
implanted into the humanized or immunodeficient mouse model to obtain results that are more 
similar to the original patient.  
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3. Lung cancer therapy 
Despite advances in chemotherapy, surgery, and radiation therapy, lung cancer is one of the 
leading causes of cancer-related deaths globally (148, 149). Even though there is some initial 
response with present conventional chemotherapy, patients will develop resistance and exhibit 
poor survival with prolonged usage (150). Several attempts were made to improve the survival of 
lung cancer patients using various combination therapies that have demonstrated that no further 
improvement observed, suggesting the need for specific, less toxic treatment approaches such as 
genetic alterations. Tumor suppressor genes and oncogenes are the two major genetic factors 
affecting the progression of the disease (151, 152). Hence, altering these explicit genes can 
advance the therapeutic benefit of present therapies. (153). Numerous gene therapy strategies 
have been adopted, such as the deletions of oncogenes, immune stimulation, replacement of 











there are some examples of the recently reported non-viral gene carriers for lung cancer gene 
therapy.(155-158). siRNA-encapsulated nanoformulations are being widely examined to find the 
suitable formulation, for lung cancer treatment (76, 159). For example, CYP1A1 is an important 
family member of cytochrome P450 enzymes involved in the metabolic pathways of cancer 
which is highly conserved in lung cancer. The investigators developed CYP1A1siRNA 
encapsulated cationic liposomes to inhibit the CYP1A1 gene in vivo. The cationic liposomes 
carrying CYP1A1siRNA efficiently silenced the CYP1A1 gene and inhibited tumor growth in 
BALB/c nude xenografts (77). Recently, scientists demonstrated that peptide head groups 
containing lipids are more suitable than quaternary ammonium head groups containing lipids for 
gene delivery vectors for cancer therapy. Using this peptide-based IGF-1R-siRNA delivery 
system, the effective  inhibition  of tumor growth of the A549 cell xenografts was achieved (77).  
 
Figure 1. Formation and delivery progress of PEA/anti-miR-155/HA–peptide complexes into lung cancer cells. 
HA–peptide: CSNIDARAC peptide modified HA; CSNIDARAC peptide is a targeted peptide for lung tumor sites. 
(B) Transmission electron microscopy (TEM) image of surface morphologies of the carrier. Reprinted with 













Targeted delivery of the gene and drug to tumor cells is one of the important issues to reduce 
side effects on normal cells. Numerous approaches have been developed to improve the 
selectivity and safety of cancer treatments using small peptides, antibodies, and aptamers. For 
example, scientists developed Bcl-xL shRNA complexed PAMAM dendrimers containing 
aptamer as a targeting moiety for the treatment of lung cancer (160). Yang et al. used a 
biodegradable polyester amine (PEA) and hyaluronic acid-coated gene delivery vehicle to 
deliver anti-miR-155 to lung tumors which showed promising results in both in vitro and in vivo 
(Figure 1) (79). Importantly, the Leaf Huang group developed VEGF-siRNA encapsulated 
polymetformin containing hyaluronic acid NPs which exhibited significant in vivo VEGF 
knockdown in lung cancer xenograft model (Figure 2). The results exhibited that  the  non-viral 
delivery system for VEGF knockdown in a lung cancer xenograft model improved  the efficiency 
of tumor suppression (161). Recently, scientists developed a G11 peptide-functionalized 
supramolecular self-assembled pVEGF-shRNA loaded NPs for lung tumor-targeted therapy 
(162). Zhao and his team also developed PLK1siRNA loaded poly(l-histidine) containing hybrid 
nanoplatforms to deliver PLK1 siRNA to NSCLC tumors (73). Spermine is a tetra amine with 
outstanding biocompatibility. However, its usage in gene delivery is poor due to its low gene 
condensation capability. The researchers developed PEG-diacrylate modified spermine and 
folate functionalized NPs for gene therapy of lung cancer (163). More recently, delivery and 
controlled regulation of genes via exosomes is recognized as a potential therapeutic method in 
the treatment of cancer. Researchers have developed an exosome-based microRNA-497 delivery 
platform for anti-cancer therapy in a microfluidic 3D lung cancer model (164). In another study, 
scientists developed MDM2 siRNA loaded triazine-modified dendrimer NPs for gene delivery, 











Scientists also used mesenchymal stem cells derived nanoghosts as a selective, safe non-viral 
gene delivery vehicle. pDNA complexed-nanoghosts inhibited the growth of metastatic 






















Figure 2. (A,C) Anionic HA‏siRNA mixture was condensed by cationic PolyMet into a negatively charged 
PolyMet/(HA‏siRNA) complex. (B,D) DOTAP/cholesterol cationic liposomes were added to the complex to form 
lipid coating, then DSPE-PEG and DSPE-PEG-anisamide were used to liposome by the post-insertion method to 
form LPH-PolyMet final NPs. (E) The daily calculated tumor volumes. (F) The daily calculated tumor weights. (G) 
Visual observations of the H460 tumor sizes in each treatment. DOTAP 1,2-dioleoyl-3-trimethylammonium-propane 
chloride salt. DSPE-PEG: 1,2-distearoryl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol-2000) 
ammonium salt. Reprinted with permission from (161). 
 
 
There are several other non-viral vectors used for the delivery of various nucleic acid materials 
for lung cancer (166-173). Another most common genetic alteration happen in the lung cancer is 
associated with the tumor suppressor genes. For example, tumor suppressor gene TUSC2/FUS1 
(TUSC2) is inactivated in lung cancer. However, no drug development approach is available for 
targeting the loss-of-function genetic deviations. Roth JA and his team developed a systemic 
gene therapy approach by using a TUSC2-expressing plasmid vector packaged in DOTAP:chol 
nanovesicles. They found that following the tumor treatment with DC-TUSC2, some major 
changes in the intrinsic pro-apoptotic pathway happened (174, 175). These nanovesicles were 
administered intravenously in the patients bearing lung cancer and the results showed an 
improvement in delivering TUSC2 genes to both human primary and metastatic tumors safely 
(176). Among several existing polymeric transporters, PEI was mostly exploited to transfer 
genes for both in vitro and in vivo transfection. For example, scientists used PEI to develop a pH-
sensitive in vivo selective gene delivery system to transfer p53DNA at the tumor site. A single 
administration of p53DNA nanocomplex along with laser radiation, significantly inhibited tumor 
growth and prolonged median survival (177). Gold NPs also used to deliver p53DNA to lung 
cancer cells (178). Several other studies also demonstrated that the p53-based gene delivery is 











research updates, non-viral based gene therapy has shown promising potential for further 
developments towards lung cancer gene therapy.  
The combination of physical approaches including ultrasound with non-viral vectors has shown 
great opportunity to enhance the transfection efficiency of these materials. For example, plasmid- 
binding cationic lipid microbubbles were combined with ultrasound mediated gene delivery to 
direct miR-133a to the tumor site. The results demonstrated that the transfection efficiency in 
cell cultivation and hind limb tumor xenografts significantly increased. The transfection 
enhancement could be associated with the potential of ultrasound in disturbing the cell 
membrane which facilitate the cell entry of nucleic acids (74).  
 
4. Breast cancer therapy 
There are several strategies to treat breast cancers based on the severity and the mechanisms 
involved in the pathogenesis including autophagy and apoptosis (183). Although there are 
several non-viral vehicle for breast cancer gene delivery including cationic-liposomes, polymers, 
PLGA, inorganic material, exosomes, and engineered stem cells (184), we have focused on 
recent developments for designing novel carriers for breast cancer gene therapy.  
Diverse categories of non-viral vehicles used for RNA (small interfering RNAs & microRNA) 
delivery. For instance, for the more sustained release of siRNA, Segovia et al. developed PBAE-
siRNA biodegradable hydrogels in a framework built on PAMAM dendrimer cross-linked with 
dextran aldehyde. They observed significant levels of gene knockdown in the breast cancer 
tumor model (185). In another study, the investigators established an inventive thermosensitive 
controlled release hydrogel loaded with a gene for breast cancer treatment (Figure 3) (90). Chol-











breast cancer (186). Further, investigators used multi-functional mesoporous silica NPs (MSNP) 
for specific transfer of siRNA to the tumor site. In their study, they observed a safe delivery of 
Pgp-siRNA and Dox together with PEI-PEG-decorated MSNP at the tumor site while the tumor 
growth was reduced by inhibiting Pgp expression (187). Pgp plays a crucial role in the induction 
of tumor resistance following the treatment with Dox and its down-regulation has attracted great 
attention for gene therapy. A similar study was carried out by another group using MSNs-TPGS 
NPs (188).  
 
Figure 3. (A to C) Schematic presentation for the preparation of thermosensitive hydrogel and its in vivo 
therapeutic effect. (D) Retention of free gene and encapsulated gene in hydrogel at the local injection site after 
intradermal injection into mice and fluorescence emission. Sur-ASON: survivin antisense oligonucleotide; F127: 
Pluronic, poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) copolymer; PHB: Poly[(R)-3-













More recently, Zhang and his team developed a novel RNA-triple-helix hydrogel for the 
treatment of triple negative breast cancers (TNBCs). The researchers incorporated 
CXCR4siRNA and an RNA-triple-helix in the hydrogels NPs without synthetic polycationic 
reagents for the treatment of breast cancer (189). Amorphous calcium carbonate fusion 
nanospheres fabricated with CaIP6 NPs were efficient in carrying genes to the tumor site. 
Scientists showed that AKT1 siRNA loaded CaCO3/CaIP6 nanocomplexes substantially 
inhibited tumor growth (190). Similarly, a polypeptide containing LAH4-L1-siMDR1 loaded 
nanocomplexes displayed significant tumor growth inhibition when used along with PTX. In this 
study,  high MDR1 gene silencing efficacy was observed in the tumor-bearing nude mice (98). 
Enormous efforts are still underway for developing novel and effective gene delivery systems 
based on biocompatible nanomaterials to transfer the target genes to the tumor site (167, 191, 
192). For example, researchers  have developed an elastin-like recombinant (ELR) and specific 
MUC1 aptamers for intracellular delivery of the MUC1 gene to breast tumors (193). More 
recently, the same group developed a double protection tumor-specific nanomaterial device for 
gene therapy in breast cancer (86). The functionalized peptides/ligands can also improve the 
delivery of nucleic acid-complexed NPs to tumors (95, 194, 195). Recently, researchers 
established CD49f peptide-fabricated aerosol polyplexes for gene delivery to tumors of both 
breast and lung over-expressing the D49f gene (88). In another study,  scientists developed a 
polycation-decorated bowl-shaped magnetic assembly (b-MNP-PGEA) for magnetic resonance 
imaging (MRI)-guided synergistic gene therapy for the treatment of breast cancer (89). Ruan et 
al. developed a cross-linked BPEI/plasmid DNA nanocomplexes, which resulted in great 
transfection efficiencies both in vitro and in vivo. Moreover, these polyplex have shown 











group synthesized a novel PEGDGA-functionalized hPAMAM nanocomplex for effective gene 
delivery to breast cancer (196). Cell-penetrating peptide (CPP)-containing and EGFR-siRNA 
loaded nanobubbles showed synergism with ultrasound irradiation mediated EGFR-siRNA 
delivery to TNBC (197). Zhou et al also developed CD105-conjugated targeted cationic 
microbubbles for antiangiogenesis gene therapy for breast cancer (198). Similarly, endostatin 
loaded and CD105 antibody conjugated immunoliposomes were prepared for antiangiogenic and 
imaging therapy (199).  Gu et al. also prepared CD44 antibody conjugated and anti-MDR1/P-gp 
short hairpin RNA complexed nanosystem for reversal of drug resistance. These nanocomplex 
enhanced the therapeutic efficacy of adriamycin in in vivo model (200). Porous silicon NPs (pSi) 
were additionally reformed with PEI to yield pSi-PEI particles, which then complexed with 
siRNA for an effective treatment for breast cancer (201). Recently, Devulapally et al. showed 
that PEGylated-PLGA/PIE NPs fused with the TK-NTR gene are able to decrease tumor growth 
when treated with other prodrugs in TNBC xenograft in vivo (92). 
Recent discoveries may lead the researchers to redefine the role of p53 in breast cancer. Several 
studies have shown that p53 alterations increase the therapeutic efficacy of current 
chemotherapeutics. For example, Cationic β-cyclodextrin-polyethylenimine-Dox (PC-Dox) 
conjugates were prepared for carrying wt p53 plasmid in the form of PC-Dox/p53 
nanocomplexes. This nanocomplex could inhibited the tumor growth synergistically and 
prolonged the survival of drug-resistant breast tumors mice (202). In another similar study, the 
investigators proved that the co-delivery of p53 DNA and AVPI peptide enabled a complete 
arrest of tumor growth when used in combination with a reduced dose of Dox. In their study, 
they modified AVPI peptide not only to enable it to penetrate to tumor cells but also acts as a 











several studies demonstrating that the  p53 mediated gene therapy for breast cancer treatment is 
an efficient approach in cancer gene therapy (204, 205). Overall, the combination of 
chemotherapy along with gene therapy may enhance the therapeutic effects against breast cancer. 
 
5. Brain tumor-targeted gene delivery 
There are other categorization methods for brain tumors including primary and secondary 
tumors. Primary tumors originate from meninges, glands, nerve and other brain cells, while 
secondary tumors originate from other parts of the body and spread to the brain (206). The most 
common brain cancers are glioma, neuroblastoma, meningioma, vestibular schwannoma and 
pituitary adenoma. The brain tumors can be primary diagnosed using MRI, CT scan, angiography, 
skull X-ray and biopsy. Despite enormous advances in the field of pharmaceutics and 
radiotherapy, the brain cancers cannot be completely cured.  
Polymer-based carriers are accounted as one of the most effective carriers in drug delivery (207-
209). Wilhelm et al. reported that active targeting with inorganic NPs such as gold NPs is the 
most effective strategy for drug delivery in cancer therapy (210, 211). Moreover, gene delivery is 
accounted as a hopeful strategy for brain cancer treatment. One of the most important obstacles 
in brain drug delivery is the blood-brain barrier (BBB). Therefore, there are many efforts to 
overcome this barrier including functionalization and modification of non-viral gene delivery 
vectors (212, 213). The modification leads to the transcytosis and endocytosis of vectors through 
cell-penetrating peptides (CPP) mediated transmembrane transport, adsorptive-mediated 
endocytosis and receptor-mediated endocytosis (214). There are some receptors on the surface of 
brain capillary endothelial cells (BBB cells), including transferrin, insulin receptors and low-











Angiopep-2, avidin, lactoferrin and transferrin are able to act as targeting ligands for these 
receptors and would be considered as promising molecules for transcytosis through the BBB. 
There are several reports indicating the role of cell-penetrating peptides and polyarginine (R8) to 
enhance the transcytosis of cargo through the BBB and cell uptake.  
Several non-viral carriers have been investigated for gene delivery to the brain including 
monocytes owing to biocompatibility and passing through the BBB (101, 215, 216) as well as 
cationic polymers such as PEI (217), polyamidoamine (PAMAM) dendrimers, poly(amino acids 
cationic liposomes (218) and positive bubbles decorated with folate (105, 214).  Despite 
significant advantages, each carrier system may suffer from drawbacks such as cytotoxicity and 
low transfection efficiency. (214). PEGylated polyplexes have been developed to overcome the 
brain delivery of nucleic acids. These delivery systems  not only decrease the cytotoxicity of 
polyplexes but also improve the gene transfection (219). Abdallah et al. demonstrated that 
among the PEI with molecular weight of 25, 50 and 800 kDa, the PEI with 25 kDa has shown 
higher and prolonged gene transfection efficacy with less toxicity in mice brain (220). However, 
modification of PEI with other molecules such as myristic acid enhances transfection and 
survival time in tumor animal models (217). 
There are several various approaches to improve the transfection efficiency of non-viral carriers 
for brain delivery.  For example,  Jiao et al. (221) designed a multifunctional cargo for gene 
delivery (Figure 4). They used angiopep-2 as a transcytosis factor and conjugated R8 to a 
targeting motif of MMP2 as an inducer of cell uptake and cancer microenvironment targeting 
agent. The polypeptide was supposed to be released from the MMP-2-responsive peptide since 
the MMP2 is upregulated in tumor microenvironment. They prepared a cholesterol coupled 











160 nm and +10-40 mV, respectively. The cargo showed high transfection efficacy and uptake in 
U251 cells and high accumulation in mice bearing glioma (221).  
 
Figure 4. (A) Schematic illustration for the formation of micelle/DNA. (B) Size distribution and TEM image of 
the micelles. (C) Real-time in vivo fluorescence imaging of U251 tumor-bearing nude‏ mice‏ intravenously‏
administrated‏ with‏ PBS(I), YOYO-1(II),‏ ch-K5(s-s)R8/pEGFP-YOYO-1(III), and ch-K5(s-s)R8-An/pEGFP- 












Noteworthy, Shi et al. also used Angiopep-2 to enhance BBB penetration. They decorated a 
polymersome containing poly(ethylene glycol)-b-poly(trimethylene carbonate-co-dithiolane 
trimethylene carbonate)-b-poly(ethylenimine) (ANG-CP) with Angiopeo-2 and loaded the cargo 
with anti- polo-like kinase 1 (PLK1) siRNA (N/P ratio of 0.4, siRNA loading 9.6 wt%, particle 
size of 115 ± 1.9 nm, zeta-potential + 0.4 mV). In vitro BBB transcytosis assay showed 
significantly higher transcytosis of targeted nanocarrier (ANG-CP-siRNA) as compared to naked 
siRNA and CP-siRNA. Interestingly, ANG-CP Scrambled siRNA induces 2.5 fold higher cell 
uptake compared to non-targeted CP siScramble on U-87 MG cells as a model cell line. 
Pharmacokinetic studies showed a significantly higher circulation time of targeted and non-
targeted CP-siPLK1 compared to the naked siPLK1. However, targeted CP siPLK1 accumulated 
in tumor site and not in the brain parenchyma and the targeted nanocarrier significantly silenced 
the oncogene and decreased the tumor growth with no bodyweight loss compared to the CP 
siRNA and naked siRNA. This gene carrier system did not show toxic effects on the other tissues 
such as spline, liver, heart, kidney and lung (222). 
Besides BBB transcytosis, multidrug resistance could be considered as one of the major 
obstacles in the efficacy of chemotherapeutic agents in glioblastoma multiforme (GBM). For 
example, multidrug resistance-associated protein 1 (MRP1) plays critical roles in chemo- and 
radio-resistance. Tong et al., prepared a PEI coated porous silicon NP with an average particle 
size of 169-173 nm and zeta potential of + 50 mV. They loaded NPs with the MRP1-siRNA with 
the release rate of 70% between 24 to 48 h and injected them into the mice bearing GBM (U87 
cell). The release profile of NPs between 24 to 48 h was 70% (100). PEI- Si NP- MRP1-siRNA 
showed significantly higher loading and cellular uptake in U87 cells as compared to the non-PEI 











MRP1 silencing and doxorubicin sensitivity in U87 cells treated with PEI- Si NP- MRP1-siRNA 
compared to non-siRNA cargo. Noteworthy, the knock-down of the multidrug transporter P-
glycoprotein (Pgp) induces G2/M arrest in leukemia cells (223). The investigation of MRP1 
silencing in CD-1 nude mice bearing U87 cells showed that PEI-Si NP- MRP1-siRNA 
significantly decrease the level of MRP1 mRNA and protein compared to the non-siRNA cargo 
(100). It seems that the release profile of siRNA between 24 to 48 h has critical role in gene 
delivery efficiency. On the other hand, NPs with the same size showed different gene delivery 
efficiency due to release profile between 24 to 48 h. For example, chitosan (224) and PLGA NPs 
(225) led to the only 10% release of siRNA between 24 to 48 h. There are some reports on the 
comparison of biocompatibility of PEI with other polymers. For example, Oh et al. revealed that 
the cytotoxicity of PEI vectors was significantly higher than R7L10. R7L10 is a short 
amphiphilic peptide micelle that is chemically synthesized (107). They used a suicide gene, 
herpes simplex virus thymidine kinase (HSVtk), for the gene delivery to GBM. DNA with the 
negative charge interacts with the positive surface of R7L10 micelle, while hydrophobic drugs 
such as bevacizumab, an angiogenesis inhibitor, can be entrapped in the core. Erythropoietin 
(Epo) transcription enhances in hypoxia conditions (central core of GBM) while nestin intron 2 
(NI2) leads to gene expression in glioblastoma and neural stem cells. It was demonstrated that 
the stability of pEpo–NI2–SV–HSVtk/R7L10 was considerably higher than pEpo–NI2–SV–
HSVtk/PEI after heparin treatment. Another result obtained from the Oh et al. study was the high 
DNA protection from the nuclease and significantly less C6 cell toxic effects by pEpo–NI2–SV–
HSVtk/R7L10 compared to the pEpo–NI2–SV–HSVtk/PEI. Moreover, the transfection efficacy 
of R7L10 was significantly less than PEI and lipofectamine, while PEI induced a significantly 











with pEpo–NI2–SV–HSVtk/R7L10 had a synergistic effect on tumor growth inhibition. Hence, 
it seems that R7L10 is safer than PEI and conjugation with Epo enhances its gene and drug 
delivery efficacy in hypoxia condition (107).  
Dendrimers have been considered as effective drug delivery carriers and polyamidoamine 
(PAMAM) is one the most well-known dendrimers in drug delivery. It seems that primary and 
tertiary amines in dendrimer play a critical role in DNA condensation and release (226). 
However, there are controversial reports on the safety of dendrimers owing to their positive 
surface charge, especially for G2–G4 dendrimers (227, 228). It has been shown that PEGylated 
lactoferrin-dendrimer-DNA has shown significantly less toxicity and higher transfection efficacy 
than non-PEGylated ones. Interestingly, they showed that brain uptake and transfection efficacy 
of the lactoferrin conjugated complexes were significantly higher than the transferrin substituted 
ones (229). Bai et al., prepared an arginine-PAMAM carrier to deliver human interferon beta 
(IFN-β) using human IFN-β plasmid to glioma tumors in mice. IFN-β plays anti-tumor efficacy 
through the induction of apoptosis in the tumor. Their findings showed that R-PAMAM- pORF-
IFN-β plasmid DNA significantly decreases tumor size in xenograft brain tumor model induced 
by U87MG cells and cancer cells such as U87 and Neuro2a while did not decreases survival rate 
in HT22 cells. However, R-PAMAM- pORF-IFN-β induced significantly higher levels of IFN-β 
gene expression and apoptosis in the brain tumor models in mice compared to the R-PAMAM- 
pORF groups (230). Furthermore, functionalization of PEGylated PAMAM/pEGFP with 
chlorotoxin (N/P= 3:1) significantly enhances the animal survival rate, biodistribution, gene 
expression and apoptosis following the intravenous injection in the brain tumor compared to 











There is some reports showing that the PEGylation and modification of liposomes with OX26 
(BBB transporting facilitator) and chlorotoxin (brain tumor targeting) containing the plasmid 
hTERTC27 (N/P=6:1, particle size 120 nm) leads to significantly decrease in tumor volume and 
enhanced survival rate as compared to liposome/C27, liposome/OX26/C27, liposome/ 
chlorotoxin/OX26/pEGFP. These findings confirmed the importance of dual targeting in a 
successful gene delivery (218). Furthermore, Huang et al. developed a superparamagnetic iron 
oxide NPs decorated with hyaluronic acid and functionalized with TNF-related apoptosis-
inducing ligand (TRAIL) and CD44. The complex significantly decreases the tumor size and 
enhanced survival rate in the orthotopic xenograft cancer BALB/cAnN.Cg-Foxn1nu/CrlNarl 
mice model (102). 
As mentioned earlier, transferrin is a considerable receptor on the surface of brain blood 
endothelial cells and glioma while the presence of excess transferrin induces competition with 
endogenous transferrin molecules. Therefore, Kuang et al. developed a sequence that targets 
transferrin (His-Ala-Ile-Tyr-Pro-Arg-His) while interacts with the distinct binding site of 
transferrin receptor (232). Since the transportation of T7 increases in the presence of excess 
transferrin, Kuang et al. attached the T7 via PEG to a peptide dendrimer (dendrigraft poly-l-
lysines (DGLs)) and red fluorescent protein (RFP) plasmid was used as the reporter gene. They 
formed polyplexes with the particle size of 141.6 ± 52 nm and zeta potential of + 3.19 mV. The 
results showed the enhancement of U87 cellular uptake by the T7 complex as compared to the 
T7. (232). 
There is a well-known method for the preparation of peptide carrier and template with a secure 
biological activity and stability. D-amino acids are more stable than L-amino acids while they 











will approach to the native sequence (233). Wang et al. synthesized a retro-inverse peptide from 
the parent sequence of C-end rule (CendR) “RPPREGR” and conjugated it to modified PEI and 
PEG to prepare a non-viral vector. The sequence specifically recognizes neuropilin-1 receptor 
which is involved in angiogenesis and over expressed on glioma cells. Since the pORF-hTRAIL 
gene enhances survival time in U87 glioma-bearing BALB/c nude mice through the apoptosis of 
glioma cells, this plasmid was used to form the complexes with the peptide platform. The cell 
viability of the complex was significantly less than PEI on U87 cells. The peptide prepared in 
this study has shown higher stability, remarkable ligand-receptor affinity for glioma cells and 
biological activity than parent peptide. However, the transfection efficacy and anticancer effect 
of the complex containing RPPREGR was significantly higher than the parent RPPREGR vector 
owing to receptor targeting of the retro-inverse peptide (233). Another example for the 
application of peptide motifs as gene delivery systems was reported by Zhan et al..They 
conjugated cyclic arginine-glycine-aspartic acid- (cyclic RGD) to a PEG-PEI polymer and the 
plasmid DNA (pORF-HTRAIL) was used for complexation. The complexes were formed with 
the average particle size of 73 nm. RGD as an important factor in neovascularization has shown 
high affinity for integrin αvβ3 and it could be used as a targeting ligand for glioblastoma cells 
(U87). However, the nanocarrier induces significantly prolonged survival time in glioblastoma 
bearing nude mice (234). One major point is that the cyclic RGD has shown higher affinity and 
selectivity with its receptor compared to RGD through conformational restraint (235, 236). Lei et 
al. investigated whether the applying of disulfide bound to conjugate the RGD-PEG and PEI core 
may enhance the transfection efficacy in U87 brain tumor-bearing BALB/c nude mice. They 
used the plasmid pDsRED-N1 to form the complexes at N/P ratio of 12 with the particle size of 











particle size and zeta potential due to the reduced surface charge. Moreover, the transfection 
efficacy of RGD-PEG-SS-PEI/pDsRED-N1 was significantly higher than the non-sulfide vector 
due to the detachment of PEG from the complex following the cleavage of disulfide linker in 
GSH rich microenvironment at tumor cell (237). Furthermore, other researchers designed a 
PEGylated peptide NP with CPP (stearylated transpartan 10 sequences) and nominated it as 
NickFect (NF). The structure was prepared using the attachment of Cys to Boc-l-Lys(Mtt)- OH. 
The negative charge of phosphorylated NF and increment of helicity lead to the enhancement of 
transfection efficacy. Moreover, the results of gene delivery in BALB/c mice bearing 
glioblastoma showed higher gene transfection efficacy than naked pDNA. (104). Another 
example of gene delivery via peptide vehicles is the complexation of herpes simplex virus-
thymidine kinase-ganciclovir (HSV-TK/GCV) plasmid and TRAIL plasmid into poly L-lysine-
PEI. It has been shown that HSV-TK/GCV is a suicide gene which has synergistic effect while it 
is used with TRAIL (238). They confirmed that the increase of polymer has a direct relationship 
with the decrease of cell viability and poly L-lysine enhances cell viability. Intratumoral 
injection of MSC (tumor tropism) transfected with polyplex-TRAIL- HSV-TK (N/P 1:3) 
enhances cell viability, rat survival and VEGF marker while decreases apoptosis as compared to 
the polyplex-TRAIL, polyplex-HSV-TK and PBS in glioma-bearing SD rats (99). However, the 
complex containing SV-TK with erythropoietin and nestin intron 2 (NI2) showed that its 
complexation with reducible poly oligo D-arginine has significantly less cytotoxicity than PEI 
even at hypoxic condition. Furthermore, the polyplex induced significantly higher apoptosis and 
tumor size decrease in an intracranial glioblastoma rat model (106). Overall, the targeting 












6. Gastrointestinal cancer therapy 
The focus of this section is on the synthetic non-viral delivery vectors evaluated in in vivo 
gastrointestinal cancers including colorectal and gastric cancers. These nano carriers have been 
employed as delivery vehicles for RNA silencing of oncogenes, DNA delivery of tumor 
suppressors, apoptosis inducers, suicide genes or immune-stimulatory molecules.   
 
6.1. Colorectal cancer therapy 
Colorectal cancer is the third most deadly diagnosed cancer in the world due to its metastasis 
(239, 240). Various types of non-viral carriers have been employed for colorectal cancer therapy 
(241-243). However, combination therapy, including co-delivery of drug and gene by NPs have 
attracted more attention these years (244, 245). Wang et al. (116), investigated the potential of 
co-loaded NPs with anticancer drugs and genes as a promising strategy for colorectal cancer 
therapy. They used poly (ethylene glycol)-ε-poly(caprolactone) block copolymer for co-loading 
of 5-fluorouracil (5-FU) and pEGFP (DNA) as DFNC. Investigating in vivo gene transfection of 
NCs (nanocarrires) such as DNC (DNA nanocarrier) and DFNC showed more anticancer 
efficiency at 72 h rather than 24 h resulted from the NCs sustained release. The results of in vivo 
gene delivery indicated that around 60% of the cells were transfected by the gene. The in vivo 
study was done on BALB/c nude mice and qualitative and quantitative findings confirmed the 
efficiency of NCs for in vivo gene therapy of colon cancer. Antitumor efficacy of NCs was also 
exhibited significantly reduced the tumor growth in FNCs and DFNCs groups (around 320 mm
3
 
at day 21) rather than free 5-FU (852 mm
3
).  
Moreover, siRNA-based gene therapy is a promising alternative modality in colorectal cancer 











biodegradability as a carrier for different drugs (246, 247). Modifying this copolymer with 
amphiphilic DOTAP (DMP) has shown remarkable stability and safety for colon cancer gene 
therapy (248, 249). For example, the cationic self-assembled DOTAP and MPEG-PCL hybrid 
micelles safely and effectively deliver Bcl-xl siRNA and Mcl1 siRNA to C26 cells in BALB/c 
mice bearing colon cancer xenografts. DMP/siRNA also demonstrated significant therapeutic 
efficacy in inhibiting tumor growth induced by apoptosis activation. Bcl-xl and Mcl1 genes are 
anti-apoptotic genes from Bcl-2 family which play a crucial role in suppressing apoptosis. 
DOTAP containing DMP micelles has shown great stability over 96 hours with remarkable 
transfection efficiency. Their hydrodynamic average size and zeta potential were 144.8 nm and 
+46.4 mV, respectively. The highest binding efficiency of siRNA was achieved at the highest 
DMP: siRNA (N/P) ratio of ≥ 30. Intratumoral injection of DMP/siRNA in C26 xenograft animal 
model showed significant reduced tumor weight, including DMP/siMcl1 complex (0.34 ± 0.06 g, 
p < 0.01), DMP/siBcl-xl complex (0.42 ± 0.08 g, p < 0.01) compared to control group (0.85 ± 
0.09 g) and DMP group (0.76 ± 0.11 g), confirming the tumor growth inhibitory effects of 
DMP/siRNA complexes. Moreover, no significant changes were reported on the other organs 
such as heart, liver, spleen, lung, or kidney mainly due to partial masking of positive charges of 
DOTAP. During the self-assembly process of micelles, DOTAP is embedded inside the MP 
copolymer. This phenomenon causes the shielding of the positively charged head groups of 
DOTAP. Moreover, it is resulted in less serum protein binding and ultimately more transfection 
efficiency (248). Also, DMP micelles were used for the delivery of the survivinT34A gene (S-
T34A, a suicide gene) for colon cancer gene therapy (249). Targeting the apoptosis pathways 
plays a critical role in cancer treatment. Survivin is an apoptosis inhibitor (126, 250, 251) 











growth and resistance to cancer therapy. However, the lack of Thr34 phosphorylation leads to the 
breakdown of caspase-9-survivin protein complex and activation of caspase-dependent apoptosis 
(247-249). In order to prepare a nonphosphorylated mimic of survivin, Thr34 was changed to 
Ala (T34A) via site-directed mutagenesis, (252, 253). Following the infection of cancer cells by 
survivin-T34A mutant, activation of the suicide effects and spontaneous apoptosis occurred. The 
mean particle size and the zeta potential of DMP were 46 ± 5.6 nm and +41.8 ± 0.5 mV, 
respectively. The highest DNA binding efficiency of DMP was observed at DMP: DNA ≥ 10 
(weight:weight) ratio. The transfection efficiency was 37±2.5% compared to 32± 3% for the 
golden standard of PEI25kDa. Intraperitoneal injection of DMP/S-T34A (125 mg/5 mg) to 
female BALB/c mice with the abdominal cavity metastases of C-26 colon carcinoma resulted in 
the significant reduce of tumor weight and cancer-associated ascites. These findings indicated 
the therapeutic efficacy of DMP/S-T34A in suppressing the abdominal cavity metastases of C-26 
colon carcinomas. It was suggested that apoptosis activation is the major anticancer mechanism 
of DMP/S-T34A in vivo.   
Despite the advancement in targeted drugs, the metastatic CRC (mCRC) patients are still 
suffered from poor prognosis and more mortality. However, improved pharmacokinetic profiles 
of targeted drugs, such as siRNA can be considered as promising achievements in mCRC 
treatment. In this regard, Sousa et al. (254), reviewed the systemic siRNA delivery strategies in 
mCRC, focusing on PLGA NPs. They reviewed strategies to enhance the siRNA encapsulation 
efficiency into PLGA, including co-encapsulation by cationic polymers and the other less toxic 
materials. These co-encapsulants facilitate endosomal escape, which in turn improved delivery 
efficiency. For example, Sureban et al. (255), used PEI as a co-encapsulants to enhance 











particles has shown the average size of around 200 nm and practical loading efficiency of 7.45 
µg/mg. NP-siDCAMKL-1 was injected intratumorally into HCT116 xenografts in male athymic 
nude mice (NCr-nu/nu). DCAMKL-1 (Doublecortin and CaM kinase-like-1) is a microtubule-
associated protein kinase and has been proposed as the gastrointestinal stem cell marker with 
high expression levels in gastrointestinal cancers (256). DCAMKL-1 silencing could be achieved 
by activating the tumor suppressors such as microRNAs (let-7a, miR-200a and miR-144) and the 
down-regulation of c-Myc, KRAS, ZEB1, ZEB2 and Notch-1. NP-siDCAMKL-1 administration 
into colorectal cancer tumor xenograft model inhibited the tumor growth by silencing the proto-
oncogenes including Notch-1 and c-Myc through the activation of miR-144 and let-7a, 
respectively. NP-siDCAMKL-1 can also suppress cancer metastasis due to effect on epithelial–
mesenchymal transition (EMT) by Snail, Slug, ZEB1, ZEB2 down-regulation via miR-200a 





 cell surface markers (257). 
Taken together, NP-siDCAMKL-1 as a novel promising anti-cancer therapeutics could inhibit 
tumorigenesis and metastasis of CRC by knocking down the specific oncogenes through the 
regulation of various miRNA-dependent mechanisms. Furthermore, the same group reported the 
liposomal carrier for siDCAMKL-1 in order to inhibit CRC xenograft growth previously. 
However, PLGA-siDCAMKL-1 has shown the same efficiency or more than the liposomal 
formulations in the silencing of oncogenes including c-Myc. 
It has been extensively reported that dendrimers are promising nanomaterials for cancer gene 
therapy due to their unique properties. Dufes et al. (258) systemically administrated 
polypropyleneimine dendrimers (PPIG3) loaded with tumor necrosis factor A (TNFA) gene, 











adenocarcinoma. This treatment demonstrated the synergistic antitumor effects of TNFA-loaded 
PPIG3 compared with the alternative treatments. This delivery system led to the remarkable 
regression and long-term survival in 100% of tumor models.  
 
Figure 5. (A) Measured tumor volume size at different time. (B)  Photograph of mice bearing the tumors. 













PAMAM dendrimers were also used for the delivery of survivin antisense oligonucleotide 
(survivin-ASODN) in colorectal cancer subcutaneous xenograft models (259). PAMAM-
survivin- ASODN significantly down-regulated survivin expression and tumor growth.  
Nanogels are another type of non-viral gene carriers used for the delivery of therapeutic 
oligonucleotide in vivo. Nanogel containing heparin and cell-penetrating peptide R8 were grafted 
to low-molecular-weight PEI for the delivery of human TNF-related apoptosis-inducing ligand 
plasmid (phTRAIL). HPR/phTRAIL complex exhibited safe and efficient hTRAIL plasmid 
delivery and significant tumor growth suppression in the in vivo model of the abdominal 
metastatic colon carcinoma (260).  
Plasmids expressing vesicular stomatitis virus matrix protein (pVSVMP)-loaded heparin-
polyethyleneimine (HPEI) nanogels were also showed significant anti-tumor efficacy.  
pVSVMP/HPEI complexes significantly arrested the C-26 colon carcinoma growth in both 
intraperitoneal and intravenous injection, which resulted in the inhibition of abdominal and 
pulmonary metastases, respectively. Tumor suppression is induced by apoptosis induction, 
resulting in the prolonged survival rate. pVSVMP/HPEI complexes showed high transfection 
efficiency, low cytotoxicity, and improved blood compatibility compared with  PEI25kDa (261).  
In another strategy, the combination of immunogenic chemotherapy was studied by oxaliplatin 
(OxP), the first-line chemotherapy of colorectal cancer, and plasmid DNA of PD-L1 trap- loaded 
lipid-protamine DNA NPs. This strategy led to a transient and local expression of PD-L1 trap in 
the tumor microenvironment and synergistically inhibited the tumor growth with OxP in an 
orthotopic colorectal cancer model. Interestingly, the combination of OxP and PD-L1 trap does 
not stimulate the spleen accumulation of Th17 cells, despite the combination of OxP and anti-











safe cancer immunotherapy approach which overcomes the limitations of checkpoint inhibitor 
immunotherapy (262).  
Liposomes have also been extensively used in gene therapy of gastrointestinal cancers due to 
remarkable properties, including biocompatibility (263). An injectable plasmid DNA of 
telomerase-specific oncolytic adenovirus (TelomeScan) expressing GFP was loaded in liposome 
(Lipo-pTS) and investigated in HCT116 tumor-bearing mice to take the advantages of oncolytic 
virotherapy and overcome their limitations including elimination by the immune system. Lipo-
pTS showed the strong tumor-specific antitumor effect independent of coxsackie and adenovirus 
receptor (CAR) and decreased adenovirus-neutralizing antibodies (AdNAbs) in immune-
competent mice. (264). In another study, cationic liposome-targeted the murine endostatin gene, 
antiangiogenic agent, (Lipo/mEndo) suppressed the colon cancer growth and prolonged survival 
times of intraperitoneally injected mice.  Lipo/mEndo inhibited ascites formation and tumor foci 
numbers on mesentery of the mice resulting in the reduction of tumor burden in the abdominal 
cavity (265). Cationic liposomes were also employed to encapsulate the plasmid encoding 
prostate apoptosis response protein 4 (par-4). The administration of this formulation resulted in 
the over-expression of par-4, activation of apoptosis and more susceptibility to 5-FU in hT29 
tumor-bearing nude mice (266).  
In addition to various materials used for the delivery of nucleic acids for colorectal carcinoma, 
electrotransfection is a promising route for facilitated delivery of genes into the target cells. In a 
study conducted by Vidic et al., the effect of miRNA to knock down the K-ras on K-ras 
expression level and the growth of colorectal carcinoma cell line was evaluated using 
electrotransfection. The results showed the potential of electroporation as a simple and 











effects. Therefore, electro gene therapy could be considered as an effective strategy to direct the 
genes to the target cells and organs (122). 
 
6.2. Gastric cancer therapy 
Gastric cancer is the second most malignant cancer worldwide with the poor five-year survival of 
30% (267). A range of nanoparticulate systems have been investigated for efficient and safe 
delivery of genes to gastric cancer models. For example, calcium phosphate NPs (CPNPs) were 
used to deliver a novel fusion suicide gene, yCDglyTK, which is regulated by a cancer-specific 
CEA promoter and a CMV enhancer (CV) (268-270). It was observed that CPNPs specifically 
delivered the suicide gene to the CEA positive gastric cancer cells and significantly inhibited the 
growth of gastric tumor xenograft models following the 5-FC administration. CPNPs-CV-
yCDglyTK system can also be encouraging in the treatment of other cancers with CEA over-
expression  alone or in the combination with radiopharmaceuticals or other conventional 
therapies.  
Furthermore, RNA-based nanoformulations have recently attracted considerable attention as a 
new paradigm of in vivo cancer therapy due to chemically and thermostatic stability and 
desirable and specific in vivo characteristics. For instance, Cui et al. constructed a 
multifunctional RNA NP to transfer BRCAA1 siRNA to gastric cancer MGC803 xenograft 
model. This targeted theranostic NPs composed of three-way junction (3WJ) of bacteriophage 
phi29 motor pRNA, folic acid as targeting ligand, Alexa647 as a fluorescent image marker and 
BRCAA1 siRNA. FA-pRNA-3WJ-BRCAA1 siRNA NPs significantly led to in vivo gastric 
cancer regression and in situ fluorescence imaging of tumor without toxicity in the non-targeted 











Drug resistance to anti-HER-2 medications in gastric cancer treatment resulted in the 
development of other treatment strategies. The combination of multiple therapies like gene-, 
immune-, and photothermal-therapy was reported through siRNA@CPG@Gold Nanoshell. Gold 
nanoshells were used for the delivery and photothermal release of HER-2-siRNA and 
immunoadjuvant of CpG oligodeoxynucleotide in MFC gastric cancer. Multidimensional 
treatment strategy based on gold nanoshell has shown more effectiveness rather than 
monotherapy in gastric cancer models (272).   
Cationic polymers including linear or branched PEI have been extensively applied for gene 
therapy in vitro and in vivo. The branched form is preferable due to the high cationic charge and 
transfection efficiency (273). A gastric cancer-targeting NP for siRNA delivery and MRI 
applications was synthesized by the conjugation of a single-chain variable fragment of CD44v6 
(scFvCD44v6) to polyethylene glycol-grafted PEI modified with superparamagnetic iron oxide 
(PEG-g-PEI-SPION). The targeting of scFvCD44v6-PEG-g-PEI-SPION in vivo was confirmed by 
MRI, which was encouraging for simultaneous diagnosis and treatment of gastric cancer (274). 
PEG-g-PEI-SPION with the promising results was also used by Chen et al. for the delivery of 
siRNA targeting CD44v6. This target was designed for the prevention and treatment of gastric 
cancer metastasis and in vivo MRI gene tracking (275).The results showed the capability of 
PEG-g-PEI-SPION as a highly efficient contrast agent in MRI applications in vivo.  
 
7. Liver cancer therapy 
Hepatocellular carcinoma (HCC) is another deadly cancer worldwide due to the late diagnosis 
and the impaired and insufficient treatments. Therefore, it is necessary to develop the carriers 











formulated one of the advanced non-viral carrier called targeted lipopolymer for encapsulation of 
interleukin (IL)-12. This system has demonstrated enhanced transfection efficiency and the 
higher survival in mice bearing BNL (undifferentiated murine hepatocarcinoma). The targeted 
lipopolymer consists of PLGA/DOTAP conjugated to asialofetuin (AF) ligand and loaded with 
IL-12 gene. The transfer of immunostimulatory gene is a potent strategy for cancer therapy. 
Interleukin (IL)-12 is one of the most powerful immunostimulatory cytokines with the 
considerable anticancer effects (279, 280). Asialofetuin (AF) is also an excellent ligand for the 
specific recognition of asialoglycoprotein receptor (ASGPR) over-expressing in the 
hepatocarcinoma cells. Targeted-NPs demonstrated five- to 12-fold improved transfection 
efficiency in comparison with non-targeted complexes or naked plasmid pCMV IL-12, 
respectively. This is associated with the maximal levels of IL-12 and interferon-γ in the mice 
sera on the day 14 after the injection. AF-NPs inhibited the tumor growth by stimulating the 
natural killer (NK) cells through the releasing of IFN-γ which is essential for antitumor activity 
of  IL-12  (278). 
Designing the targeted vectors for specific delivery to the liver with high transfection efficiency 
is the main obstacle for HCC gene therapy. To circumvent these limitations, Xue et al. (281), 
prepared dual targeting NPs to targeted delivery of RASSF1A gene to HCC via ASGPRs and 
external magnetic field (Figure 6). In this regard, Gal-CMCS-Fe3O4-NPs were synthesized by 
modification of Fe3O4 NPs with biocompatible and biodegradable carboxymethyl chitosan 
(CMCS) and conjugation to galactose (Gal) ligands through free amino groups of CMCS. Ras 
Association Domain Family 1A (RASSF1A) is the prominent tumor suppressor gene which is 
involved in the Ras signaling pathway and have shown crucial role in apoptosis, microtubule 











its promoter is associated with the risk of‏ several cancers including HCC. It can also be 
a predictive factor for poor HCC prognosis. In vivo efforts to re-express RASSF1A has shown 
the arrest of  HCC growth as well as the improved sensitivity of HCC cells to mitomycin (282).  
 
Figure 6. (A) Schematic illustration of the entry of chitosan-Fe3O4-NPs inside the nucleus of cell. (B) Orthotopic 
transplantation of hepatocellular carcinoma in mice. The arrow marks the position of the small magnet. Reprinted 
with permission from (281). 
 
 
Gal-CMCS-Fe3O4-NPs have shown the average size of 40.1± 5.3 nm and the zeta potential of 











endocytosis of targeted carriers is affected by the NPs size (284), NPs with a diameter of < 50 
nm are selectively targeted to the hepatocytes while NPs with a diameter of > 140 nm could be 
uptake by Kupffer cells. Gal-CMCS-Fe3O4-NPs were stable at pH=7 and demonstrated the 
strongest DNA binding at physiological pH. The optimal DNA binding was observed at the 
weight:weight ratio of 3:1. Transfection efficiency of pcDNA6.2mir-EGFP-loaded Gal-CMCS-
Fe3O4-NPs in HCC tissue in the presence and the absence of an external magnetic field was 
about 40.8% and 29.7%, respectively, suggesting the efficiency of dual-targeting of NPs in the 
specific tumor accumulation. For in vivo studies, nude mice with orthotopically transplanted 
HCC were treated with intravenous injection of the Gal-CMCS-Fe3O4-NPs/pcDNA3.1(+) 
RASSF1A complex and intraperitoneal injection of MMC along with the applying an external 
magnetic field to the tumor site. These mice showed the smallest tumor size, the most percentage 
of apoptotic cells, and up-regulation of caspase-3 expression in tumor tissue compared with the 
other groups. Re-expressing of RASSF1A using dual targeting NPs proposes a new promising 
approach for HCC gene therapy through increasing the sensitivity of HCC cells to chemotherapy.  
Using the gold NPs for miR-375 delivery has also been reported for the HCC gene therapy (284). 
miR-375 regulates the gene expression and acts as a tumor suppressor macromolecule. It has 
been reported that miR-375 down-regulation is associated with different tumors, including 
gastrointestinal cancers (285). However, re-expression of miR-375 suppresses 
hepatocarcinogenesis and HCC malignancy (247). The surface of gold NPs was coated by a PEG 
layer for stabilizing the particles and covalent binding to miR-375 and labeled with Cy3 
fluorescent dye for fluorescence imaging. Gold NP-miR-375 had an average size of 53 ± 8 nm 











tumor mouse model and primary HCC tumors demonstrated the safe and enhanced delivery of 
miR-375 to tumor tissue resulting in the significant increase of therapeutic efficacy.   
Poly (beta-amino ester) (PBAE) NPs are another carrier which investigated by Zamboni et al. for 
specific and efficient DNA delivery to HCC. 2-((3- 
aminopropyl) amino) ethanol end-modified poly(1,5-pentanediol diacrylate-co-3-amino-1-
propanol) (known as „536‟) at carrier to plasmid ratio of 25 (w/w) demonstrated specific DNA 
delivery to a heterogenic HCC population and HCC xenograft model. pEGFP-N1 (eGFP) 
plasmid DNA was used as a reporter gene. The average hydrodynamic size and zeta potential of 
the carrier system at C/P ratio of 25 were 157 ± 3 nm and +18 ± 0.3 mV, respectively. The nano-
vehicle was intratumorally injected to subcutaneous Huh-7 xenografts in athymic nude mice. It 
was suggested that biodegradable 536 NPs would also be appropriate for systemic or trans-
arterial delivery due to its small size which preferentially localized in tumor through EPR effect 
(126).     
In another effort for HCC gene therapy, a multifunctional NP targeted for HCC was designed to 
deliver TRAIL gene in mice (251). These self-assembled lipid-bilayer structures (LCPP NPs) are 
composed of the calcium phosphate (CaP) and protamine core, which act as a pH stimuli-
responsive and TRAIL nuclear localization agent, respectively. Moreover, The Ca ions released 
from CaP reverse the TRAIL resistance. HCC-targeting peptide (SP94) was also used for 
targeted delivery of NPs. Finally, TNF-related apoptosis induced by efficient TRAIL delivery 
and targeting of both the tumor and the adjacent tumor microenvironment resulted in the 
significant HCC tumor inhibition. Co-delivery of TRAIL and PTEN gene by zein NPs as an 
FDA-approved protein with a high proportion of hydrophobic and polar amino acids has also 











with DNA and cell membrane, thereby high bioavailability of loaded genes in HCC rat liver 
tissue has been observed. Besides TRAIL, other apoptotic inducers have been delivered for HCC 
gene therapy. DNA encoding tBid, a pro-apoptotic mitochondrial factor, was interacted with a 
nanopolymer based on folic acid grafted PEI600-CyD (Cyclodextrin) named H1. A modified 
human α-fetoprotein (AFP) promoter, EA4D, was fused with tBid to achieve pGL3-EA4D-
tBid/H1. HCC tumor model studies showed the best activity and specificity in AFP-producing 
HCC treatment with the minimal toxicity in nude mice (287). 
Various studies‏have shown the successful delivery of siRNA through NPs in HCC models in 
vivo, although they have not entered to clinical trials yet. siRNA-lipid NPs (siRNA-LNPs) were 
reported to target YAP (Yes-associated protein), an oncogenic transcription factor, in a 
genetically engineered mouse (GEM) HCC model. YAP suppression leads to the arrest of the 
rapid proliferation of tumor cells, and then acquire the characteristics of hepatocyte 
differentiation in advanced HCC (288).  Due to the high specificity and low toxicity of siYAP-
LNPs, it is expected that this delivery system could be used for delivery of siRNA or shRNA to 
inhibit multiple targets in HCC.  
In order to develop a novel approach for improved cancer immunotherapy, tumor-targeted lipid-
dendrimer-calcium-phosphate (TT-LDCP) was designed for dual-targeting of siRNA against 
immunosuppressive factors (the immune checkpoint PD-L1) and pDNA encoding the 
immunostimulating cytokine IL-2. TT-LDCP NPs led to enhanced tumoral infiltration and 
stimulation of CD8
+
 T cells, improved cancer immunotherapy, and regression of HCC (289).  
Another alternative strategy for hepatocellular carcinoma gene therapy is hydrodynamics-based 
gene delivery procedure. This method has been tested in several studies due to its simplicity, 











the liver. In a study conducted by Kamimura and his colleagues, a diphtheria toxin fragment A 
(DTA) gene-expressing plasmid was transferred using the hydrodynamics-based procedure. The 
results demonstrated a substantial inhibition of hepatocellular carcinoma occurrence in mice 
treated with hydrodynamic-based gene therapy 0 and 2 months after gene delivery (128). Since 
ultrasound microbubble sonoporation have shown great potential for gene delivery, a ternary 
nanodroplet composed of perfluoropentane/C9F17-PAsp(DET)/miR-122/PGA-g-mPEG (PFP-
7TNDs/miR-122) was prepared and evaluated for the transferring of microRNA-122 (miR-122) 
for hepatocellular carcinoma treatment. The results showed that the treatment of the cells with 
such system combined with ultrasound irradiation increased the miR-122 expression level by 30-
fold in human HCC xenografts (130). Hence, these methods have shown potential for further 
studies to develop safe and efficient gene therapy approaches.   
 
8. Prostate cancer therapy 
Prostate cancer is the fourth most common cancer and the second most extensive cancer in males 
leading to the mortality of around 300,000 individuals per year. Almost 200,000 new patients 
have been diagnosed per annum. The late diagnosis of prostate cancer is the primary cause of 
death (290, 291). Based on the stage and severity of the tumor, different treatments can be 
suggested to the patient including prostatectomy, radiotherapy, hormone therapy, chemotherapy, 
gene therapy, and a combination of them. The most recent procedure is gene therapy that mainly 
initiated via transferring a new gene to achieve destruction or fixation of cancerous cells (292-
294). Transferrin and lactoferrin are two iron-binding proteins that widely used as targeting 
ligands for prostate cancers (295, 296). Another promising approach for prostate targeting is 











microenvironment. Integrin receptors are supposed to be over-expressed on prostate cancer cells 
(297, 298). Prostate-specific membrane antigen (PSMA), integrins, and prostate stem cell 
antigen (PSCA) are the glycoprotein which could be targeted by various ligands (299, 300). 
Zhang et al. (138) studied an effective and biocompatible drug and gene delivery system using a 
RGD-PEG-DSPE/CaP. They achieved the LCP-RGD NPs by modifying the NPs, which contains 
a calcium phosphate (CaP) core, dioleoyl phosphatidic acid (DOPA) and RGD modified 
poly(ethylene glycol)-conjugated distearoyl phosphatidylethanolamine (RGD-PEG-DSPE). They 
used this system for co-delivery of GRP78 siRNA and docetaxel (DTXL) in other to cure the 
PC-3 CRPC. In another study, Dong et al. (142) tried to develop an effective co-delivery of 
docetaxel (DTX) and plasmid DNA (pDNA) for combination chemotherapy. They studied a cell-
penetrating peptides (CPPs) modified lipid-PEI hybrid NPs (LPNs) and evaluated a modified 
RKKRRQRRR peptide (TAT), DTX, pDNA and LPNs (TAT-DTX/pDNA LPNs) in PC3 cancer 
cells (in vitro) and in a murine prostate cancer model (in vivo).‏ Wang et al. (301) investigated in 
vitro and in vivo anti-tumor effects of nanobubbles carrying androgen receptor (AR) siRNA. In 
this study, they combined those nanobubbles with ultrasonic irradiation in order to test them on 
androgen-independent prostate cancer (AIPC). They concluded that those nanobubbles could be 
used as gene vectors for the treatment of AIPC. In a study by Wu et al. (139) they prepared an 
anti-tumor targeted FoxM1 siRNA-loaded cationic nanobubbles (CNBs) conjugated with an 
A10-3.2 aptamer (siFoxM1-Apt-CNBs). They concluded that their synthesized NPs could 
potentially act as a promising targeted gene delivery system for prostate cancer therapy. Rak et 
al. (302) suggested a group of cationic polyprenyl derivatives with different lengths of 
polyprenyl chains as DNA vehicles. They provided a group of lipofecting agents for in vitro and 











on DU145 human prostate cancer cells.  In two different studies, Williford et al (144) and Wu et 
al. (146) worked on prostate tumor regression. Willfort et al. designed a PEGylated structure for 
DNA micellar NPs in order to achieve balanced colloidal stability and improved transfection 
activity (144). On the other hand, Wu et al. evaluated the possibility of using aptamer-modified 
NPs (APT-NPs) to deliver microRNA (miRNA) to prostate cancer cells to demonstrate their 
tumor-targeting efficiency (146). 
Some other studies tried to find a meaningful interaction between the prostate cancer and other 
organs using cytokines. For instance, Zolochevska (303) et al. analyzed the role of interleukin-27 
(IL-27) in the interactions between prostate cancer and bone. They used the IL-27 gene delivery 
by applying sonoporation (sonodelivery) in vivo in order to treat and reduce the growth of 
prostate cancer at a bone metastatic site. Hattori et al. (304) achieved the elevated efficiency of 
transfection using the adhesion of extracellular matrix (ECM) to the complex of DNA/lipid 
(nanoplex). Once the ECM proteins coated on the nanoplex, they could improve DNA 
transfection activity in cells. They showed that Fn-coating nanoplexes could facilitate 
transfection of prostate tumor cells. 
The use of alternative approaches including sonoporation for prostate cancer gene delivery has 
attracted great attention due to the high transfection efficiency and safety. For example, the 
delivery of IL-27 was carried out using sonodelivery with a biocompatible polymer complexed 
to pDNA to reduce prostate tumor growth in an immunocompetent TC2R C57/BL6 model (140). 
Since there are several therapeutic ultra sound waves for clinical applications, those which  
operates at frequencies of 1-3 MHz and use relatively low intensities (0.1–2 W/cm
2
)  could be 
considered for in vivo transfection. Using such therapeutic-ultrasound (TUS), a human tumor 











achievements have shown the potential of these routes for further studies towards the clinical 
translation.  
 
9. Co-delivery systems 
The most common treatment of cancers is chemotherapy while having various challenges and 
side effects including the lack of selectivity to the cancer cells and toxicity to the healthy cells 
(305). Different approaches such as gene therapy and combination therapy have been suggested 
to circumvent these limitations (111, 285, 306). Combination therapy may decrease the toxicity 
of each agent by reducing the individual drug-related dose. In this field, co-delivery of drug and 
gene-based NPs have attracted more attention (244, 245). The most common used nanosystems 
for co-delivery are polyplexes, which are made by the electrostatic interactions among the 
polymers, drugs, and nucleic acid materials. Wang et al. (116) investigated the potential of co-
loaded NPs with anticancer therapeutics and genes as a promising strategy for the treatment of 
colorectal cancer. They used poly (ethylene glycol)-ε-poly(caprolactone) block copolymer for 
co-loading of pEGFP (DNA) and 5-fluorouracil (5-FU). The average hydrodynamic size of DNA 
and 5-FU co-loaded nanocarriers (DFNC) was increased to around 145 nm with a zeta potential 
of +15.4±3.2 mV in the case of co-loaded particles compared with +27.6±2.9 mV in the case of 
control nanocarriers. Electrostatic interaction of DNA with the outer layer of cationic NCs is the 
reason for increasing the size and neutralizing the surface charge. The gene entrapment 
efficiency was around 90%, indicating the high DNA-loading capacity resulting in the higher 
gene expression in vivo. Drug entrapment efficiency was also higher than 80%, suggesting the 
stability of NC. Moreover, the in vivo stability evaluation of NCs in the serum demonstrated no 











of protein corona may be induced by the PEG coating. Release studies exhibited that over 80 % 
of DNA was released at 48 h while the same release profile for the drug was achieved at 72 h, 
suggesting the faster release of DNA due to their orientation on the outer layer of NCs. 
Interestingly, in a new promising strategy, a triblock copolymer micelle based on N-succinyl 
chitosan–poly-L-lysine–palmitic acid (NSC–PLL–PA) was employed by Zhang et al. (250) for 
co-delivery of doxorubicin and siRNA against P-glycoprotein. It has been observed that the 
emerged synergistic effect is even more efficient than co-treatment of chemotherapeutics and 
siRNA (116, 193, 244, 285). Dox–siRNA-micelle had an average size of 170 nm and a zeta 
potential of +3.2 mV. Furthermore, encapsulation and loading efficiency of DOX were 95.32 ± 
2.06% and 16.09 ± 0.17%, respectively. siRNA binding efficiency was achieved at the best N/P 
ratio of 20:1. siRNA electrostatically interacted with the cationic backbone of PLL while the 
hydrophilic shell of NSC provides enhanced biocompatibility. On the other hand, DOX was 
encapsulated in the hydrophobic core of PLA. Following 24 h post-injection, tumor 
accumulation of Dox–siRNA-micelles was approximately complete due to the particle size and 
instability at low pH. In another study, researchers employed survivin shRNA and erlotinib 
(gene/drug) co-loaded delivery nanoformulation for the treatment of drug resistance EGFR-
mutated non-small cell lung cancer (78). More recently, this strategy was further improved by 
the other groups where the researchers used chitosan-based nanocomplex to deliver survivin 
shRNA, erlotinib, and heptamethine cyanine dye (Cy7, as a photothermal agent) in one stage for 
triple-combination therapy of NSCLC (307). 
 











In recent decades, considerable attention has been directed to the non-viral delivery of nucleic 
acid materials for gene therapy (308, 309). The breakthrough of immunotherapy, new advances 
in genomics and discoveries in re-programming the somatic cells to induced pluripotent stem 
cells (iPS) have created a new paradigm in medicine, which resulted in the re-introduction of 
gene therapy as a powerful tool for the treatment of several various diseases from cancer to viral 
infections. Recently, CRISPR (clustered regularly interspaced short palindromic repeat)/Cas 
(CRISPR-associated) genome editing systems have attracted considerable attention due to their 
potential to edit the genome based on RNA-guided nuclease (310-313). Among the several kinds 
of CRISPR/Cas systems, the type II systems attracted more attention for human applications. 
Only in these systems, Cas9 protein is an essential compartment for DNA interference. 
Generally, this system contains a nuclease protein (Cas9) and a guide RNA (gRNA) (213). 
Since, the gRNA could be replaced by sgRNA (synthetic chimeric single guide RNA), the Cas9 
protein could be directed to the target site using sgRNA which consequently leads to the 
induction of double-stranded DNA breaks (DSBs). Finally, the major pathways of repair 
mechanism in the cells are responsible for inducing the alterations. This simple, robust, user-
friendly, specific, and efficient system has enabled researchers to create models for various 
diseases as well the novel therapeutic approaches (314-317).  
Generally, there are three different approaches for CRISPR/Cas 9 delivery (318). The ultimate 
goal is to transfer the whole system into the cells. However, the ribonucleoprotein complex could 
be transferred to the cells via different routes. The first choice is to deliver sg RNA with Cas9 
protein. This strategy is simple and straightforward which provides the Cas9 protein inside the 
target cells with no need for transcription or translation. The positive charge of Cas9 protein in 











in a major obstacle for efficient delivery of such ribonucleoprotein material. On the other hand, 
Cas9 protein is a large macromolecule with a molecular weight of ~160 kg/mol which might be 
obtained through the expression in bacterial hosts. The production of the protein in the bacterial 
hosts might be expensive and the endotoxin contamination could be considered as an additional 
obstacle for their large-scale production. Various non-viral carriers have been used to transfer 
such platforms into the target cells including gold NPs, graphene oxide, carboxylated branched 
poly (β-amino ester) NPs, β-cyclodextrin-conjugated low-molecular-weight polyethylenimine, 
microbubble-nanoliposomal particles, pH-responsive silica–metal-organic framework (SMOF) 
hybrid NPs consisting of both silica and zeolitic imidazole framework (ZIF) as well as cell-
penetrating peptides and DNA nanoclews (319-331).  
Since the difficulties for efficient delivery of Cas9 protein reduces the transfection efficiency of 
sgRNA and Cas9 protein, the alternative strategy is to use the Cas9 mRNA with sgRNA. For 
efficient delivery of Cas9 protein and sgRNA, the delivery platform must be able to transfer a 
large positively charged protein (Cas9) and a negatively charged nucleic acid (sgRNA) together. 
Designing such delivery systems is not simple. The second approach includes the delivery of two 
mRNA molecules with similar biophysical properties that facilitates the design of delivery 
systems. Besides, the introduction of Cas9 mRNA into cells does not need to be entered into the 
cell nucleus for subsequent transcription. Therefore, the main advantage for this approach is the 
quick onset of action. The transient expression of Cas9 mRNA in the cytosol along with the 
quick onset of Cas9 action make this approach an attractive way for the researchers to reduce the 
off-target effects associated with the long time presence of Cas9 protein inside the cells. 











Various non-viral delivery strategies have been employed to transfer Cas9 mRNA with the 
sgRNA together including zwitterionic aminolipid NPs (332-335) and branched-tail lipid NPs.  
Since there are several problems for efficient delivery of Cas9 protein, Cas 9 mRNA and 
sgRNA, the third method have been introduced which includes the design of a plasmid encoding 
Cas 9 and sgRNA inside the cells. The stability of plasmid-based CRISPR/Cas9 systems is really 
higher than protein or mRNA making these systems more attractive for in vivo applications. 
However, there are several major obstacles reducing its clinical applications. This system could 
be able to cross the nuclear membrane and access the transcriptional machinery of the cells. 
Since the transcription of the plasmids and the production of Cas9 protein and sgRNA need more 
time rather than the direct introduction of these macromolecules into the cells, the delay in the 
onset of therapeutic action is expected. In addition, the off-target effects associated with the 
long-term production of Cas9 protein is more probable rather than the previous methods.  Also, 
the risk of the integration of plasmid into the genomic materials may reduce their potential for 
wide clinical applications. However, several non-viral delivery systems have been introduced for 
the efficient transfer of plasmid-based CRISPR/Cas9 systems including dendrimers, polymers, 
polypeptides and polysaccharides such as PLGA as well as lipid encapsulated gold NPs, 
polyethylenimine magnetic NPs and multifunctional nucleus-targeting core-shell artificial 
viruses (336-341). 
The physical approaches to transfer the CRISPR/Cas9 system for in vitro studies have shown 
great results. However, these strategies, including electroporation and microinjection, could not 
be used in human clinical trials (342). The application of viruses (e.g., adeno-associated virus) is 
an efficient way to transfer these systems into the human target sites, but the drawbacks of the 











obstacles hampering the efficient delivery of such systems into the cells, their tendency to the 
dividing cells versus post-mitotic non-dividing cells could be considered as an opportunity to 
transfer these platforms into the cancer cells. Altogether, the great potential of CRISP/Cas9 
system for the treatment of several diseases and the development of various delivery approaches 
have opened up new horizons to translate the lab-scale achievements to the clinical applications.  
 
11. Conclusions 
In recent decades, various oligonucleotide-based therapeutics have been introduced for human 
clinical applications. This novel category of therapeutic materials includes antisense 
oligonucleotides and aptamers as well as siRNA-based medications. The clinical applications of 
these new drugs are the result of breakthrough discoveries in molecular biology. However, the 
translation of these achievements to the clinical applications is substantially dependent on the 
development of efficient and safe delivery systems. An optimized delivery system for nucleic 
acids should be able to form a stable structure outside the cells and release the payloads at the 
specific site of action. In addition, the toxicity of the delivery vehicle must be tolerable by the 
human cells. The biophysical properties and the pharmacokinetic characteristics of the vehicles 
are the other significant points which determine the potential of delivery system for human 
applications. In order to improve these properties, stealth technology using various materials 
such as PEG and targeting strategies have been introduced. Using these approaches, the 
biophysical characteristics of the carriers could be modified and their pharmacokinetic properties 
might be improved. Generally, polymer and dendrimer-based delivery systems have shown 
higher transfection efficiency (5, 25, 53). However, their toxicity is the major concern for the 











modification strategy is focused on the reduction of cytotoxicity through the modulation of 
cationic charge or designs the biodegradable polycationic compounds. In addition, these 
materials suffer from the low targetability for the specific cells or tissues (346). Therefore, the 
addition of targeting moieties on these materials could be considered as an effective way to 
improve their properties. These materials are appropriate delivery systems for the formation of 
complexes based on the electrostatic interaction between the nucleic acid and carrier. On the 
other hand, lipid-based carriers have demonstrated higher biocompatibility rather than the 
polymeric delivery systems (347, 348). These delivery systems have shown great potential for 
clinical applications due to their low toxicity. However, the transfection efficiency of such 
materials is generally lower than the polymeric compounds. Therefore, the major approaches to 
improve the properties of these vehicles are focused on the augmentation of their transfection 
efficiency. Similar to the polymeric delivery systems, lipid-based materials need the targeting 
moieties for efficient transfer of nucleic acid to the target cells or organs. Although the toxicity 
of lipid-based delivery systems is lower than the polycationic polymers or dendrimers, they may 
induce inflammatory responses following systemic administration. The translation of these 
materials for commercial application needs a scalable production process which leads to the 
commercial products with highest batch-to-batch uniformity. The most recent clinical trial on the 
application of mRNA as a potential vaccine for SARS-CoV-2 has been conducted by LNPs 
which shows the importance of this category of delivery system for human application (36). To 
date, cationic lipids have shown great efficiency for the delivery of these materials compared 
with the other non-viral carriers. It seems that the rapid developments of gene editing platforms 











limiting their administration (349). Therefore, the shoulder-to-shoulder development of these two 
fields is essential for the clinical translation of gene editing platforms.  
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